|
Index of reports
> Serious Reactions (153)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Epirubicin serious reactions. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of 153 Next >>
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-08-20
Patient:
Reactions: Abdominal Pain, Vomiting, Hypersensitivity, Nausea, Skin Toxicity, Mucosal Inflammation, Fatigue, Diarrhoea, Hepatotoxicity, Neutropenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Epirubicin
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Herceptin
Dosage: loading dose
Indication: Breast Cancer
Herceptin
Dosage: maintenance dose
Lapatinib
Dosage: arm b
Administration route: Oral
Indication: Breast Cancer
Lapatinib
Dosage: arm c
Administration route: Oral
Paclitaxel
Indication: Breast Cancer
Possible Epirubicin side effects in 74 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16
Patient: 74 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in 73 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-16
Patient: 73 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2, cyclic
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13
Patient: female
Reactions: Oesophageal Candidiasis
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2011-10-14
End date: 2011-10-14
Cyclophosphamide
Start date: 2011-09-16
Cyclophosphamide
Start date: 2011-09-02
Cyclophosphamide
Start date: 2011-09-30
Epirubicin
Start date: 2011-09-16
Epirubicin
Start date: 2011-09-30
Epirubicin
Start date: 2011-09-02
Epirubicin
Start date: 2011-10-14
End date: 2011-10-14
Other drugs received by patient: Neupogen; Taxol; Tamoxifen Citrate; Docetaxel; Acetaminophen and Codeine Phosphate; Docetaxel; Acetaminophen and Codeine Phosphate
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-13
Patient:
Reactions: Dyspnoea, Brain Natriuretic Peptide Increased, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction
Drug(s) suspected as cause:
Adriamycin PFS
Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
Indication: Breast Cancer
Cyclophosphamide
Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
Indication: Breast Cancer
Docetaxel
Indication: Breast Cancer
Doxorubicin Hydrochloride
Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
Indication: Breast Cancer
Epirubicin
Dosage: 75-100 mg/m2
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Paclitaxel
Indication: Breast Cancer
Trastuzumab
Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
Indication: Breast Cancer
Possible Epirubicin side effects in
Reported by a consumer/non-health professional from Japan on 2012-08-10
Patient:
Reactions: Injection Site Vasculitis, Injection Site Pain, Injection Site Phlebitis
Drug(s) suspected as cause:
Epirubicin
Indication: Breast Cancer
Fosaprepitant Dimeglumine
Dosage: 150 mg, once
Indication: Prophylaxis of Nausea and Vomiting
Start date: 2012-02-06
End date: 2012-02-06
Fosaprepitant Dimeglumine
Dosage: 150 mg, once
Start date: 2012-02-27
End date: 2012-02-27
Fosaprepitant Dimeglumine
Dosage: 150 mg, once
Start date: 2012-03-19
End date: 2012-03-19
Other drugs received by patient: Cyclophosphamide
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Japan on 2012-08-09
Patient:
Reactions: Brain Natriuretic Peptide Increased, Dyspnoea, Ejection Fraction Decreased, Nail Disorder, Cardiac Failure Congestive, Infusion Related Reaction
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 mg/m2 for fac regimen and 600 mg/m2 for ac regimen
Indication: Breast Cancer
Docetaxel
Indication: Breast Cancer
Doxorubicin Hydrochloride
Dosage: 40-60 mg/m2 for fac and 60 mg/m2 for ac
Indication: Breast Cancer
Epirubicin
Dosage: 75-100 mg/m2
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Paclitaxel
Indication: Breast Cancer
Trastuzumab
Dosage: 8 mg/kg followed by maintenance (md) 6 mg/kg every 3 wks or 4 mg/kg followed by 2 mg/kg weekly md
Indication: Breast Cancer
Possible Epirubicin side effects in 74 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09
Patient: 74 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in 73 year old male
Reported by a health professional (non-physician/pharmacist) from Korea, Republic of on 2012-08-09
Patient: 73 year old male
Reactions: Hepatitis C
Drug(s) suspected as cause:
Cisplatin
Dosage: 60 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Epirubicin
Dosage: 50 mg/m2
Indication: Hepatic Neoplasm Malignant non-Resectable
Other drugs received by patient: Lipiodol
Possible Epirubicin side effects in
Reported by a consumer/non-health professional from Canada on 2012-07-30
Patient:
Reactions: Disease Progression
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Product Used FOR Unknown Indication
Epirubicin
Indication: Product Used FOR Unknown Indication
Fluorouracil
Indication: Product Used FOR Unknown Indication
Xeloda
Indication: Product Used FOR Unknown Indication
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-07-09
Patient: female
Reactions: Drug Intolerance, Tongue Neoplasm Malignant Stage Unspecified
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Neoplasm
Start date: 2011-08-01
Cyclophosphamide
Dosage: 14 days on 21 days
Start date: 2011-02-01
End date: 2011-07-01
Cyclophosphamide
Start date: 2004-12-03
End date: 2005-02-02
Doxorubicin HCL
Dosage: 9 courses
Indication: Product Used FOR Unknown Indication
Start date: 2009-02-19
End date: 2009-11-05
Doxorubicin HCL
Dosage: 8 courses
Start date: 2007-11-27
End date: 2008-06-24
Epirubicin
Indication: Product Used FOR Unknown Indication
Start date: 2004-12-03
End date: 2005-02-02
Fluorouracil
Indication: Product Used FOR Unknown Indication
Start date: 2004-12-03
End date: 2005-02-02
Taxotere
Indication: Product Used FOR Unknown Indication
Start date: 2005-03-08
End date: 2005-04-19
Other drugs received by patient: Aromasin; Navoban; Xeloda; Faslodex; Estracyt; Femara; Arimidex; Navelbine
Possible Epirubicin side effects in 63 year old male
Reported by a physician from Poland on 2012-06-27
Patient: 63 year old male
Reactions: Dyspnoea, Palmar-Plantar Erythrodysaesthesia Syndrome, Pleural Effusion, General Physical Health Deterioration, Neutropenia, Polyneuropathy, Disease Progression
Adverse event resulted in: death
Drug(s) suspected as cause:
Capecitabine
Indication: Product Used FOR Unknown Indication
Epirubicin
Indication: Product Used FOR Unknown Indication
Oxaliplatin
Indication: Product Used FOR Unknown Indication
Possible Epirubicin side effects in female
Reported by a physician from Denmark on 2012-06-26
Patient: female
Reactions: Activities of Daily Living Impaired, Sensory Disturbance, Pain
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: unk
Indication: Breast Cancer
Docetaxel
Dosage: unk
Indication: Breast Cancer
Epirubicin
Dosage: unk
Indication: Breast Cancer
Fluorouracil
Dosage: unk
Indication: Breast Cancer
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-06-25
Patient:
Reactions: Neutropenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (600 mg/m2 (every 3 weeks))
Indication: Breast Cancer
Docetaxel
Dosage: (100 mg/m2 (every 3 weeks))
Indication: Breast Cancer
Epirubicin
Dosage: (100 mg/m2 (every 3 weeks))
Indication: Breast Cancer
Fluorouracil
Dosage: (600 mg/m2 (every 3 weeks))
Indication: Breast Cancer
Other drugs received by patient: Filgrastim
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-18
Patient:
Reactions: Vomiting
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Breast Cancer Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Breast Cancer Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
Indication: Breast Cancer Stage III
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Menstruation Irregular
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Breast Cancer Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Breast Cancer Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
Indication: Breast Cancer Stage III
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-06-15
Patient: female
Reactions: Hypertransaminasaemia
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Start date: 2011-06-25
End date: 2011-09-03
Epirubicin
Indication: Breast Cancer
Start date: 2011-06-25
End date: 2011-09-03
Fluorouracil
Indication: Breast Cancer
Start date: 2011-06-25
End date: 2011-09-03
Other drugs received by patient: Levothyroxine Sodium
Possible Epirubicin side effects in female
Reported by a individual with unspecified qualification from Egypt on 2012-06-15
Patient: female
Reactions: Menstruation Irregular
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
Indication: Inflammatory Carcinoma of Breast Stage III
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Anaemia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified)
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified)
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
Indication: Inflammatory Carcinoma of Breast Stage III
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Neutropenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 mg/m2 (every three weeks) intravenous (not otherwise specified)
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: 100 mg/m2 (every three weeks) intravenous (not otherwise specified)
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: 500 mg/m2 (every three weeks) intravenous bolus
Indication: Inflammatory Carcinoma of Breast Stage III
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Febrile Neutropenia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 mg/m2 every three weeks intravenous not otherwise specified
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: 100 mg/m2 every three weeks intravenous not other wise
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: 500 mg/m2 every three week (intravenously bolus)
Indication: Inflammatory Carcinoma of Breast Stage III
Possible Epirubicin side effects in 60 year old female
Reported by a physician from Japan on 2012-06-15
Patient: 60 year old female
Reactions: Injection Site Vasculitis, Injection Site Pain, Injection Site Phlebitis
Drug(s) suspected as cause:
Epirubicin
Indication: Breast Cancer
Fosaprepitant Dimeglumine
Indication: Prophylaxis of Nausea and Vomiting
Start date: 2012-02-06
End date: 2012-02-06
Fosaprepitant Dimeglumine
Start date: 2012-02-27
End date: 2012-02-27
Fosaprepitant Dimeglumine
Start date: 2012-03-19
End date: 2012-03-19
Other drugs received by patient: Cyclophosphamide
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Nausea
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 mg/m2, every thrree weeks, intravenous
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: 100 mg/m2, every three weeks, intravenous
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: 500 mg/m2, every three weeks, intravenous bolus
Indication: Inflammatory Carcinoma of Breast Stage III
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-06-15
Patient: female
Reactions: Breast Cancer, Maternal Exposure During Pregnancy
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Breast Cancer
Start date: 2007-01-01
End date: 2007-01-01
Epirubicin
Indication: Breast Cancer
Start date: 2007-01-01
End date: 2007-01-01
Fluorouracil
Indication: Breast Cancer
Start date: 2007-01-01
End date: 2007-01-01
Possible Epirubicin side effects in
Reported by a individual with unspecified qualification from Egypt on 2012-06-15
Patient:
Reactions: Transaminases Increased
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus
Indication: Inflammatory Carcinoma of Breast Stage III
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Nausea
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 500 mg/m2 every three weeks intravenous not otherwise specified
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: 100 mg/m2 every three weeks intravenous (not otherwise specified
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: 500 mg/m2 every three weeks intravenous bolus
Indication: Inflammatory Carcinoma of Breast Stage III
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Hyperbilirubinaemia
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Breast Cancer Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Breast Cancer Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
Indication: Breast Cancer Stage III
Possible Epirubicin side effects in
Reported by a health professional (non-physician/pharmacist) from Egypt on 2012-06-15
Patient:
Reactions: Transaminases Increased
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Breast Cancer Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous bolus)
Indication: Breast Cancer Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
Indication: Breast Cancer Stage III
Possible Epirubicin side effects in female
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-06-15
Patient: female
Reactions: Alopecia, Neutropenia, Constipation
Drug(s) suspected as cause:
Cyclophosphamide
Start date: 2011-06-25
End date: 2011-09-03
Epirubicin
Start date: 2011-06-25
End date: 2011-09-03
Fluorouracil
Start date: 2011-06-25
End date: 2011-09-03
Other drugs received by patient: Levothyroxine Sodium
Possible Epirubicin side effects in
Reported by a individual with unspecified qualification from Egypt on 2012-06-15
Patient:
Reactions: Neutropenia, Haematotoxicity
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: (500 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Inflammatory Carcinoma of Breast Stage III
Epirubicin
Dosage: (100 mg/m2 (every three weeks) intravenous (not otherwise specified))
Indication: Inflammatory Carcinoma of Breast Stage III
Fluorouracil
Dosage: (500 mg/m2 (every three weeks) intravenous bolus)
Indication: Inflammatory Carcinoma of Breast Stage III
Page 1 Next >>
|
